FDA PROCESS ANALYTICAL TECHNOLOGY SUB COMMITTEE MEETING 25 TH FEBRUARY 2002 PERSPECTIVE ON PROCESS AND ANALYTICAL VALIDATION Robert S Chisholm.

Slides:



Advertisements
Similar presentations
Adapting to a changing city - The Equality Agenda Dublin 06.
Advertisements

Wir stehen für Wettbewerb und Medienvielfalt. The Virtuous Circle: New regulations, innovation and investment – How to bring Europe back to the Top Dr.
PRINCIPLES OF A CALIBRATION MANAGEMENT SYSTEM
Producing a Pharmaceutical or Biopharmaceutical
Good Manufacturing Practices Guilin, PRC Dr AJ van Zyl for Quality Assurance and Safety: Medicines Medicines Policy and Standards Health Technology and.
Statistical Process Control for the Medical Industry.
ISO 9001 : 2000.
R APID M ICRO M ETHODS PPAR 2013 Jeffrey W. Weber, PAT Project Manager Kalamazoo, MI Oct 2013.
SAE AS9100 Quality Systems - Aerospace Model for Quality Assurance
Validation Part 2: Cleaning validation
Bayesian Statistics Vague, variable, subjective to boot…
Continuous Auditing Applications for SAP/R3 Vincent Rykes City of Edmonton.
Process Analytical Technologies Subcommittee Product and Process Development: An Industry Perspective David Rudd PhD Process Technology GlaxoSmithKline.
Pharmaceutical Product Quality Assurance Through CMC Drug Development Process Presented by Darlene Rosario (Aradigm) 21 October 2003 Meeting of the Advisory.
Supplementary Training Modules on Good Manufacturing Practice
Robust and affordable process control technologies for improving standards and optimising industrial operations Pau Puigdollers Project Coordinator.
By: Muhammad Naeem Quality Assurance and Regulatory Manager
ISO 9000 Certification ISO 9001 and ISO
MIT PHARMACEUTICAL MANUFACTURING INITIATIVE (PHARMI) PHARMACEUTICAL MANUFACTURING: NEW TECHNOLOGY OPPORTUNITIES.. G.K.Raju, Ph.D. Executive Director, Pharmaceutical.
The Molecular Diagnostics Research Laboratory University of Malaya Development and Implementation of a Quality System The Molecular Diagnostics Research.
World Health Organization
QC | Slide 1 of 16 June 2006 Good Practices for Quality Control Laboratories P art 4: Inspecting the laboratory Supplementary Training Modules on Good.
PAT Validation Working Group Process and Analytical Validation Working Group Arthur H. Kibbe, Ph.D. Chair June 13, 2002.
Learnings from Pre-approval Joint Inspection of a GSK QbD Product with US-FDA & EMA and the application of Continuous Verification 17 May 2011, Beijing,
Figure 3: Process fingerprint monitoring of a bio- reactor Biopharm production methods need effective real-time monitoring and control to guarantee a low-cost,
Xcellerex … speeding medicines to people … PAT for Biologics Ensuring Quality of Biologically Produced Drugs FDA Advisory Committee on Pharmaceutical Sciences.
Internal Auditing for Small Laboratories
Total Quality Management System (TQMS) AstraZeneca Solid Dosage Facility, Plankstadt, Germany Ali Afnan AstraZeneca Pharmaceuticals Engineering Group Alderley.
FDA Regulatory Perspective on Continuous Manufacturing
Applications and benefits of PAT Steve Hammond Global Manufacturing Services Process Analytical Support Group Sandwich, UK.
©2009 RALPH SNYDERMAN 1 Personalized Health Care: The Foundation of Rational Health Reform Ralph Snyderman, MD Chancellor Emeritus, Duke University James.
Inspection Issues in the Analytical Laboratory: An FDA Perspective Yvonne McKnight Chemist US Food and Drug AdministrationPhone: x
Bob Chisholm TQMS STATISTICALLY BASED IN-PROCESS CONTROL WITH REAL TIME QUALITY ASSURANCE The AstraZeneca Total Quality Management Strategy R S Chisholm.
D. Christopher Watts, Ph.D. Office of Pharmaceutical Science, CDER, FDA Science Seminar Series for the Office of Commissioner April 9, 2004 Process Analytical.
World Health Organization
1 Supplements and Other Changes to an Approved Application By: Richard J. Stec Jr., Ph.D. February 7, 2007.
Good Manufacturing Practice. Good Manufacturing Practice Regulations Establishes minimum GMP for methods to be used, and the facilities or controls to.
Water | Slide 1 of Water for Pharmaceutical Use Part 3: Operational considerations Supplementary Training Modules on Good Manufacturing Practice.
InstantGMP: Electronic Batch Records System for GMP Manufacturing InstantGMP™ Inventory Control Module for GMP Manufacturing.
1 PAT and Biological Products Tom Layloff FDA-SGE Management Sciences for Health The views expressed here are those of the author and not necessarily.
A Qualitative Decision Making Tool to Aid in Defining the Number of Lots for a Process Validation Campaign Leslie Sidor — Amgen Inc Midwest Biopharmaceutical.
 Siemens Nederland N.V FDA13April Presented by Troy Logan at the Advisory Committee for Pharmaceutical Science meeting on April 13, 2004.
Important informations
Molecule-to-Market-Place Quality
30/02/2008 Dept. of Pharmaceutics 1 Salient Features of Quality Assurance Dr. Basavaraj K. Nanjwade M.Pharm., Ph.D Associate Professor Department of Pharmaceutics.
From Design of Experiments to closed loop control
10:00 A.M. – Noon 7 June 2004 ICH Quality Plenary Meeting.
Chapter 27 The Engineering Design Process. Learning Objectives Describe the various factors that are changing the design process Discuss the steps in.
Blend Uniformity: Update Ajaz S. Hussain, Ph.D.. Background Issue: Assuring and documenting “adequacy of mixing” operations –PQRI’s Proposal Stratified.
Forum FM308: Policy Changes Tuesday June 5 10:00 a.m. AIHA Laboratory Accreditation Policy Changes—ISO “How Do Changes Affect My Laboratory?” “What.
General Aspects of Quality assessment of multisource interchangeable medicines Rutendo Kuwana Technical Officer, WHO, Geneva Training workshop: Assessment.
Project Management Basics
The Second Annual Medical Device Regulatory, Reimbursement and Compliance Congress Presented by J. Glenn George Thursday, March 29, 2007 Day II – Track.
Module 2Slide 1 of 26 WHO - EDM Quality Management Basic Principles of GMP Part One.
1 PAT Subcommittee Closing Report 12 March 2003 Tom Layloff Acting Chair.
FDA’s Advisory Committee for Pharmaceutical Science The Subcommittee on Process Analytical Technologies (PAT): Closing Remarks Ajaz S. Hussain, Ph.D. Deputy.
Pharmaceutical Quality Control & current Good Manufacturing Practice
FDA PAT Sub-Committee of Advisory Committee for Pharmaceutical Sciences June 12-13, 2002; Gaithersburg, MD Regulatory Challenges: Post-Approval PAT Applications.
开发报批美国 FDA 的仿制药 与相关问题探讨 上海复星普适医药科技有限公司何平. 内容提要 开发仿制药的重要性和机遇 开发仿制药的重要性和机遇 开发仿制药的挑战 开发仿制药的挑战 申报仿制药的分类 申报仿制药的分类 仿制药研发团队 仿制药研发团队 仿制药的研发过程 仿制药的研发过程 QbD 在制剂开发中怎么体现.
Good Manufacturing Practice (GMP) Compliance: GMPs EXPLAINED.
CM&C Inspections The Pre-Approval Inspection (PAI) in the US 27 May 2010.
Total Quality Management Pharmaceuticals. MEDICINE/pharmaceuticals Medicine / Brand/ Product.
© G.K.Raju, Ph.D. Manufacturing Science Sept 17th 2003 QUALITY BY DESIGN: The Means To Fundamental Manufacturing Science G.K.Raju, Ph.D.
PROCESS ANALYTICAL TECHNOLOGY – A REVIEW By Mr. Akash Mali DEPARTMENT OF PHARMACEUTICS, G.I.P.E.R., LIMB, SATARA. 1.
HOLD-TIME STUDIES.
Pharmaceutical Quality Control & current Good Manufacturing Practice
Producing a Pharmaceutical or Biopharmaceutical
Producing a Pharmaceutical or Biopharmaceutical
Producing a Pharmaceutical or Biopharmaceutical
Presentation transcript:

FDA PROCESS ANALYTICAL TECHNOLOGY SUB COMMITTEE MEETING 25 TH FEBRUARY 2002 PERSPECTIVE ON PROCESS AND ANALYTICAL VALIDATION Robert S Chisholm

THE TRADITIONAL APPROACH Processes Validated at Life cycle commencement Operated/Controlled by Standard Operating Procedures (SOPs) Quality Assurance based on off-line testing of a sample of product at the end of each batch THE PAT BASED APPROACH On or at line Analysis for real time quality control of each unit operation process control throughout the batch Real time statistically based quality assurance throughout the batch Increased statistically based testing regimes provide the potential for release of product without further off-line testing

QUOTATION 1 THE NEED FOR STATISTICS Statistical thinking will one day be as necessary for efficient citizenship as the ability to read and write H G WELLS 1925

Implementation of the TQM Strategy In-Process Control & Monitoring Key Process Operations –Identification / specification of all incoming raw materials in the dispensaries (& the warehouse) –Fluid Bed Drier end point control –Continuous in-line monitoring of blending & end point control –In-line monitoring of Tablet Quality parameters against registered specifications –21CFR11 compliant data management system Real-time continuous quality assurance The platform for parametric release

Solid Dosage Facility FB Drier Milling Blender Press Coater Sieve Dispensary Wet granulationNIRNIR NIR NIR Direct Compression Figure 1

GENERALISED MODEL OF A PAT SYSTEM THE MODULES (Functionalities) Spectral (or other) data/model storage Analytical (or other) data storage Modelling Reporting (Batch and Validation Records and Storage) Statistical Process control (SPC) and Historic Trending THE MODES OF OPERATION Modelling Validation Manufacturing

GENERALISED MODEL OF A PAT SYSTEM Figure 2

CONSIDERATIONS FOR THE VALIDATION WG Regulatory status of Model source Data (Spectral analytical etc.) traceability and long term storage Traceability of spectral data, related, analytical data and model predictions for the model validation phase and its long term storage In manufacturing what form will the ‘PAT’ batch record and release data take, How can it be used by QA to release product and how would a regulatory body inspector find an audit path from it for verification The MES/SPC Activities provide process understanding and knowledge – What regulatory status if any is associated with them

FURTHER AREAS FOR DISCUSSION Registered processes (traditional) and statistically quality controlled processes Fundamental science and validation 21CFR11 and Computer validation complexity – Open and closed systems

QUOTATION FOR THE DAY THE IMPACT OF INNOVATION There is nothing:More difficult to plan :More doubtful of success :More dangerous to manage Than the creation of a new system For the initiator has The enmity of all who profit by preservation of the old institutions AND Merely lukewarm defenders in those who should gain by the new ones Machiavelli (1527)